Related Experiment Video
Updated: Aug 8, 2026

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Published on: August 30, 2014
Oral therapy with flurithromycin in ear, nose and throat infections
G B Galioto1, D Passali, G B Catalano
1Otorhinolaryngologic Department, Policlinico S. Matteo, University of Pavia, Italy.
Abstract:
In this study efficacy and tolerability of flurithromycin ethylsuccinate (FE) were evaluated in ear, nose and throat infections. One hundred and three patients were treated with FE tablets 375 mg 12-hourly for a mean duration of treatment of 8.2 days and they were divided into groups according to the pathology: pharyngitis/tonsillitis (chronic 7, acute 38), rhinosinusitis (chronic 7, acute 12), otitis (chronic 6, acute 32) and sialadenitis (acute 1). Patients evaluable for clinical efficacy were 101, among them a complete recovery was registered in 88.2%, an improvement in 9.9% and a treatment failure in 1.9%. Bacteriological evaluation was possible in 95 patients, showing the eradication of the pathogen in 94.7%. Tolerability was judged to be excellent in 81.6%, good in 15.5% and discrete in 2.9%. These results demonstrate that FE is safe and effective in the treatment of infections established on acute or chronic inflammatory states.
Insights
Flurithromycin ethylsuccinate (FE) demonstrated high efficacy and excellent tolerability in treating ear, nose, and throat infections. This antibiotic achieved significant clinical recovery and pathogen eradication in most patients, proving its safety and effectiveness.
Area of Science:
- Otolaryngology
- Infectious Diseases
- Pharmacology
Background:
- Ear, nose, and throat (ENT) infections encompass a range of acute and chronic inflammatory conditions.
- Antibiotic therapy is a cornerstone in managing bacterial ENT infections.
Purpose of the Study:
- To evaluate the efficacy and tolerability of flurithromycin ethylsuccinate (FE) in patients with ENT infections.
- To assess clinical recovery rates, pathogen eradication, and adverse events associated with FE treatment.
Main Methods:
- A clinical study involving 103 patients with various ENT infections (pharyngitis/tonsillitis, rhinosinusitis, otitis, sialadenitis).
- Patients received flurithromycin ethylsuccinate (FE) 375 mg every 12 hours for an average of 8.2 days.
- Clinical efficacy was assessed in 101 patients, and bacteriological evaluation was performed in 95 patients.
Main Results:
- Complete clinical recovery was observed in 88.2% of patients, with improvement in 9.9%.
- Bacteriological pathogen eradication was achieved in 94.7% of evaluable patients.
- Tolerability was rated as excellent in 81.6% and good in 15.5% of cases.
Conclusions:
- Flurithromycin ethylsuccinate (FE) is a safe and effective antibiotic for treating acute and chronic ENT infections.
- The high rates of clinical efficacy, pathogen eradication, and excellent tolerability support the use of FE in otolaryngology practice.
Related Concept Videos
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
Chronic Pharyngitis
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
Tonsillitis II: Management
Microbiota of the Respiratory Tract

